Gastrointestinal Cancer

In summary, we provide here the proof-of-principle that targeting FZDs with small molecule compounds is possible and effective. Future hit optimization and functional validation in disease-relevant in vitro and in vivo models will pave the way towards clinical exploration.

P=N/A, N=20, Completed, Universidad Europea de Madrid | Recruiting --> Completed

Zolbetuximab plus chemotherapy was administered to real-world patients with CLDN18.2-positive AGC with acceptable safety profiles and showed preliminary antitumor efficacy. Nevertheless, some adverse events warrant careful monitoring.

These findings unveil PFKFB4-glycolysis-EMT axis as a druggable vulnerability in PC metastasis and position bruceine A as a potential first-in-class, dual-function agent that simultaneously suppresses tumor growth and dissemination through metabolic reprogramming.

TRAP1 represented a potential biomarker and a therapeutic target in GC treatment. This study provided a new strategy for improving the efficacy of CDDP-based chemotherapy through individualized treatment approaches.

P=N/A, N=107, Active, not recruiting, Weill Medical College of Cornell University | Trial completion date: Aug 2025 --> Jun 2026 | Trial primary completion date: Aug 2025 --> Jun 2026

P=N/A, N=40, Active, not recruiting, Varian, a Siemens Healthineers Company | Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> Dec 2026

P=N/A, N=463, Completed, Hoffmann-La Roche | Phase classification: P4 --> P=N/A

P1, N=24, Active, not recruiting, University of Nebraska | Trial primary completion date: Oct 2025 --> May 2026

P=N/A, N=300, Recruiting, Ankara Oncology Research and Training Hospital | Not yet recruiting --> Recruiting

These outcomes provide an efficient ferroptosis-related gene-based diagnostic model for CRC. Nevertheless, before its use in real-time settings, more clinical studies are required to confirm its diagnostic value.

P=N/A, N=420, Not yet recruiting, Alliance for Clinical Trials in Oncology